Clinical Trial Update: A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults [Phase 1]

View source ↗

Summary

Phase 1 study of VXB-241, an RSV-HMPV bivalent vaccine, conducted by Vicebio Australia Proprietary Limited. The trial's listed population is healthy volunteers,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• VXB-241 (RSV-HMPV bivalent vaccine)

Snippet

Sponsor: Vicebio Australia Proprietary Limited | Conditions: Healthy Volunteers | Phase 1 | Status: ACTIVE_NOT_RECRUITING